Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

333 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts.
Zeidan AM, Platzbecker U, Garcia-Manero G, Sekeres MA, Fenaux P, DeZern AE, Greenberg PL, Savona MR, Jurcic JG, Verma AK, Mufti GJ, Buckstein R, Santini V, Shetty JK, Ito R, Zhang J, Zhang G, Ha X, Backstrom JT, Komrokji RS. Zeidan AM, et al. Blood. 2022 Nov 17;140(20):2170-2174. doi: 10.1182/blood.2022016171. Blood. 2022. PMID: 35797468 Free PMC article.
Current therapy of myelodysplastic syndromes.
Zeidan AM, Linhares Y, Gore SD. Zeidan AM, et al. Blood Rev. 2013 Sep;27(5):243-59. doi: 10.1016/j.blre.2013.07.003. Epub 2013 Jul 27. Blood Rev. 2013. PMID: 23954262 Free PMC article. Review.
Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.
Zeidan AM, Lee JW, Prebet T, Greenberg P, Sun Z, Juckett M, Smith MR, Paietta E, Gabrilove J, Erba HP, Tallman MS, Gore SD; Eastern Cooperative Oncology Group (ECOG) and North American Leukemia intergroup. Zeidan AM, et al. Br J Haematol. 2014 Aug;166(3):352-9. doi: 10.1111/bjh.12884. Epub 2014 Apr 9. Br J Haematol. 2014. PMID: 24712482 Free PMC article.
Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS.
Zeidan AM, Lee JW, Prebet T, Greenberg P, Sun Z, Juckett M, Smith MR, Paietta E, Gabrilove J, Erba HP, Katterling RP, Tallman MS, Gore SD. Zeidan AM, et al. Br J Haematol. 2014 Oct;167(1):62-8. doi: 10.1111/bjh.13008. Epub 2014 Jul 4. Br J Haematol. 2014. PMID: 24995683 Free PMC article.
333 results